Effect of Abrocitinib and Dupilumab on Eosinophil Levels in Patients With Moderate-to-Severe Atopic Dermatitis and With or Without Comorbid Asthma or Allergic Rhinitis: A Post Hoc Pooled Analysis of JADE COMPARE and JADE DARE

[1]  J. Silverberg,et al.  Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial , 2022, American Journal of Clinical Dermatology.

[2]  K. Matsui,et al.  Influence of the Th1 Cytokine Environment on CCL5 Production from Langerhans Cells. , 2022, Biological & pharmaceutical bulletin.

[3]  Lei Zhu,et al.  Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study , 2022, Frontiers in Medicine.

[4]  S. Ferrucci,et al.  Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease , 2022, The Journal of dermatological treatment.

[5]  S. Szymczak,et al.  Blood transcriptome profiling identifies two candidate endotypes of atopic dermatitis. , 2022, The Journal of allergy and clinical immunology.

[6]  Y. Tokura,et al.  Transient Increase in Circulating Basophils and Eosinophils in Dupilumab-associated Conjunctivitis in Patients with Atopic Dermatitis , 2021, Acta dermato-venereologica.

[7]  D. Nahm,et al.  Real Clinical Practice Data of Monthly Dupilumab Therapy in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Clinical Efficacy and Predictive Markers for a Favorable Clinical Response , 2021, Allergy, asthma & immunology research.

[8]  T. Bieber,et al.  Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial , 2021, American Journal of Clinical Dermatology.

[9]  M. M. Limberg,et al.  Involvement of Neuro-Immune Interactions in Pruritus With Special Focus on Receptor Expressions , 2021, Frontiers in Medicine.

[10]  S. Barbarot,et al.  Dupilumab‐associated hypereosinophilia in patients treated for moderate‐to‐severe atopic dermatitis , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  M. D. de Bruin‐Weller,et al.  Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry. , 2020, Journal of the American Academy of Dermatology.

[12]  G. Argenziano,et al.  Use of Dupilumab for 543 Adult Patients with Moderate-To-Severe Atopic Dermatitis: A Multicenter, Retrospective Study. , 2020, Journal of investigational allergology & clinical immunology.

[13]  C. Flohr,et al.  Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial , 2020, The Lancet.

[14]  J. Lapointe,et al.  Immunohistochemical characterisation of the IL-13:IL-4Rα axis in the skin of moderate-severe adult atopic dermatitis patients and healthy controls. , 2020, The Journal of investigative dermatology.

[15]  J. Silverberg,et al.  Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis , 2020, JAMA dermatology.

[16]  S. Seo,et al.  Retrospective Study of Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Korea: Efficacy and Safety of Dupilumab in Real-World Practice , 2020, Journal of clinical medicine.

[17]  P. Quaglino,et al.  Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real‐life Italian tertiary centre experience , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  F. Kuang.  Approach to Patients with Eosinophilia. , 2020, The Medical clinics of North America.

[19]  T. Bieber.  Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis , 2020, Allergy.

[20]  E. Peeva,et al.  Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis , 2019, JAMA dermatology.

[21]  J. Giovannelli,et al.  Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. , 2019, Journal of the American Academy of Dermatology.

[22]  John D. Davis,et al.  Conjunctivitis in dupilumab clinical trials , 2019, The British journal of dermatology.

[23]  T. Agner,et al.  Determinants of disease severity among patients with atopic dermatitis: association with components of the atopic march , 2019, Archives of Dermatological Research.

[24]  J. Silverberg,et al.  Eosinophil Count and Serum Immunoglobulin E Levels in Atopic Dermatitis: Analysis of Upadacitinib Phase 2 Study Findings: 376 , 2019, Journal of Allergy and Clinical Immunology.

[25]  L. Dagna,et al.  Eosinophils from Physiology to Disease: A Comprehensive Review , 2018, BioMed research international.

[26]  C. Holweg,et al.  Interleukin-13 in Asthma and Other Eosinophilic Disorders , 2017, Front. Med..

[27]  B. King,et al.  Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib. , 2017, The Journal of investigative dermatology.

[28]  N. Novak,et al.  IL-31 Induces Chemotaxis, Calcium Mobilization, Release of Reactive Oxygen Species, and CCL26 in Eosinophils, Which Are Capable to Release IL-31. , 2015, The Journal of investigative dermatology.

[29]  James J. Lee,et al.  Eosinophil-dependent skin innervation and itching following contact toxicant exposure in mice. , 2015, The Journal of allergy and clinical immunology.

[30]  H. Kita.  Eosinophils: Multifunctional and Distinctive Properties , 2013, International Archives of Allergy and Immunology.

[31]  J. Szepietowski,et al.  Relationship between itch and psychological status of patients with atopic dermatitis , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[32]  S. Ständer,et al.  Correlation of IL-31 serum levels with severity of atopic dermatitis. , 2008, The Journal of allergy and clinical immunology.

[33]  W. Silny,et al.  Peripheral blood eosinophilia in atopic dermatitis. , 2007, Acta dermatovenerologica Alpina, Pannonica, et Adriatica.

[34]  E. Minshall,et al.  In vivo expression of IL-12 and IL-13 in atopic dermatitis. , 1996, The Journal of allergy and clinical immunology.

[35]  Q. Hamid,et al.  Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. , 1994, The Journal of clinical investigation.

[36]  M. Uehara,et al.  Blood eosinophilia in atopic dermatitis , 1990, Clinical and experimental dermatology.

[37]  J. Silverberg,et al.  Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.